Theravance Biopharma (NASDAQ:TBPH) Shares Gap Down – What’s Next?

Theravance Biopharma, Inc. (NASDAQ:TBPH) shares gapped down before the market opened on Monday . The stock had previously closed at $17.63, but opened at $16.97. Theravance Biopharma shares last traded at $17.04, with a volume of 771,977 shares trading hands.

Analyst Upgrades and Downgrades

Several research analysts recently commented on TBPH shares. Oppenheimer downgraded shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. TD Cowen raised their target price on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a research report on Monday, March 23rd. JonesTrading reiterated a “hold” rating on shares of Theravance Biopharma in a report on Monday. Zacks Research cut Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 8th. Finally, Wall Street Zen lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. One analyst has rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, Theravance Biopharma has a consensus rating of “Hold” and a consensus price target of $21.40.

Theravance Biopharma Trading Down 2.2%

The stock has a market capitalization of $888.77 million, a P/E ratio of 7.84 and a beta of 0.17. The company has a 50-day moving average price of $16.56 and a 200 day moving average price of $17.30.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. The company had revenue of $17.70 million during the quarter. As a group, research analysts expect that Theravance Biopharma, Inc. will post 1.54 earnings per share for the current year.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 13,314 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $16.39, for a total value of $218,216.46. Following the completion of the sale, the senior vice president directly owned 232,457 shares in the company, valued at $3,809,970.23. This trade represents a 5.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.65% of the stock is currently owned by company insiders.

Institutional Trading of Theravance Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after purchasing an additional 515 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 781 shares during the last quarter. Creative Planning raised its stake in Theravance Biopharma by 6.7% in the third quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock valued at $196,000 after buying an additional 842 shares during the last quarter. State of Wyoming boosted its holdings in Theravance Biopharma by 5.7% in the second quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock worth $209,000 after acquiring an additional 1,019 shares in the last quarter. Finally, The Manufacturers Life Insurance Company boosted its holdings in Theravance Biopharma by 6.9% in the second quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock worth $174,000 after acquiring an additional 1,020 shares in the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.